Recruiting

Hyper-Personalized Medicine

Sponsor:

Sunnybrook Health Sciences Centre

Code:

NCT04602702

Conditions

Kidney Neoplasm

Carcinoma, Renal Cell

Metastatic Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The Investigators will use novel PDX (patient-derived xenograft) technology to form xenografts using material from metastatic solid tumor patients. Xenografts will be treated with a panel of drugs to determine which agent(s) yield the greatest anti-tumor effect on the xenograft.

Conditions

Kidney Neoplasm

Carcinoma, Renal Cell

Metastatic Solid Tumor

Study ID

NCT04602702

Start date

Dec 1, 2020

Status verified date

Mar, 2022

Completion date

Dec 31, 2022

Anticipated

Primary completion date

Dec 31, 2022

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Patient eligibility:

Localized solid tumor inclusion criteria:

i) Age 18+ ii) localized solid tumor irrespective of subtype undergoing curative surgery iii) Consent to provide tumor tissue for this research

Metastatic cancer inclusion criteria:

i) Age 18+ ii) metastatic cancer irrespective of subtype undergoing a needle biopsy or resection of lung, liver or brain as part of their routine clinical care.

iii) metastatic cancer irrespective of disease site undergoing a thoracentesis or paracentesis as part of their routine clinical care.

iv) measurable disease as per RECIST 1.1 criteria v) Consent to provide tumor tissue for this research

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Objective Response [ Time Frame: 3-9 months ]
  • Stable Disease Response [ Time Frame: 3-9 months ]
  • Progressive Disease Response [ Time Frame: 3-9 months ]

Central Contacts and Locations

Central contacts

Hon S Leong, PhD

416-480-6100hon.leong@sri.utoronto.ca

Sue Santillo

416-480-6100sue.santillo@sunnybrook.ca

Locations

Odette Cancer Centre

Recruiting

Toronto, Ontario, Canada, M4N 3M5

Contacts

Elyse Watkins, BSc, PGDip

416-480-6100elyse.watkins@sunnybrook.ca

Hon S Leong, PhD

416-480-6100hon.leong@sri.utoronto.ca

More Information

Sponsor

Sunnybrook Health Sciences Centre

Last update posted

Apr 5, 2022

Last verified

Mar, 2022

Keywords

  • hyper-personalized medicine
  • patient derived xenograft
  • chick embryo

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Sunnybrook Health Sciences Centre on 2022-04-05.